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While chromosomal instability is a common feature of human solid tumours, no abnormalities in genes involved in the mitotic
checkpoint have been identified. However, recently, Chfr (checkpoint with forkhead associated and ring finger), a mitotic stress
checkpoint gene, has been reported to be inactivated due to promoter hypermethylation in several types of human malignancy. To
clarify whether Chfr promoter hypermethylation is involved in gastric carcinogenesis, we investigated the promoter methylation status
of the Chfr gene in gastric cancer cell lines and primary gastric cancers. Non-neoplastic gastric epithelia from cancer-bearing and
noncancer-bearing stomachs were also examined for Chfr promoter hypermethylation to study its cancer specificity. Two of 10
gastric cancer cell lines (20%) showed Chfr promoter hypermethylation with resultant loss of expression, which could be restored by
5-aza-20 deoxycytidine treatment. Chfr promoter hypermethylation was present in 35% (25 of 71) of primary tumours and occurred
at similar frequencies in early and advanced stages. As for non-neoplastic gastric epithelia, 1% (one of 91) from noncancer-bearing and
5% (four of 71) from cancer-bearing stomachs exhibited Chfr promoter hypermethylation. Thus, Chfr promoter hypermethylation is
mostly cancer specific and frequently leads to chromosome instability in gastric cancer.
British Journal of Cancer (2004) 90, 2013–2016. doi:10.1038/sj.bjc.6601849 www.bjcancer.com
Published online 27 April 2004
& 2004 Cancer Research UK
Keywords: Chfr; hypermethylation; gastric cancer
                                                                                               
Chromosomal instability (CIN) is commonly observed in human
solid tumours, with the apparent gain or loss of large parts or
whole chromosomes, leading to DNA aneuploidy (Lengauer et al,
1997; Duesberg et al, 1999). In previous studies, CIN has been
associated in some cases with alterations in the cell-cycle
checkpoint that monitors the integrity of the spindle apparatus,
a structure critical for proper bipolar segregation of duplicated
sister chromatids at mitosis (Cahill et al, 1999). A small fraction of
CIN cancers are associated with dominant mutations in the human
homologues of yeast spindle checkpoint genes BUB1 (Cahill et al,
1998; Imai et al, 1999; Gemma et al, 2000) and MAD2 (Li and
Benezra, 1996; Cahill et al, 1999). However, BUB1 and MAD2
mutations are relatively rare, and gastric cancers frequently exhibit
DNA aneuploidy (Abad et al, 1998; Esteban et al, 1999; Imai et al,
1999; Russo et al, 2000; Tanaka et al, 2001).
Recently, the Chfr (checkpoint with forkhead associated (FHA)
and ring finger (RF)) gene, involved in the mitotic stress
checkpoint, was cloned and located to chromosome 12q24.33. Its
product, CHFR, mediates the delayed entry into metaphase
characterised microscopically by delayed chromosomal condensa-
tion (Scolnick and Halazonetis, 2000). In addition, CHFR promotes
cell survival in response to mitotic stress (Scolnick and
Halazonetis, 2000). CHFR possesses an N-terminal FHA domain,
a central RF domain and a C-terminal cysteine-rich (CR) region
(Scolnick and Halazonetis, 2000). Based on functional analysis of
Chfr deletion mutants, both the FHA and CR regions are required
for its checkpoint function. CHFR also has ubiquitin ligase activity
dependent on the RF domain (Chaturvedi et al, 2002). Northern
blot analysis of Chfr using RNA from eight colon, osteosarcoma
and neuroblastoma cancer cell lines revealed that Chfr expression
was absent in three cell lines (Scolnick and Halazonetis, 2000).
Loss of Chfr expression due to hypermethylation of a CpG island in
the promoter region has been observed in tumour cell lines and
primary cancers of the lung, oesophagus and colon (Mizuno et al,
2002; Shibata et al, 2002; Corn et al, 2003; Toyota et al, 2003).
Thus, it is possible that Chfr promoter hypermethylation is also
involved in gastric carcinogenesis.
As promoter hypermethylation of tumour suppressor or
tumour-related genes are not always cancer specific, the sig-
nificance of promoter methylation status can vary among different
genes (Waki et al, 2003a,b). In the present study, we investigated
Chfr promoter methylation status in gastric cancer cell lines,
primary gastric cancers and corresponding non-neoplastic gastric
epithelia, as well as in non-neoplastic gastric epithelia of
noncancer-bearing stomachs to clarify both the significance and
cancer specificity of Chfr promoter hypermethylation in gastric
carcinogenesis.
MATERIALS AND METHODS
Gastric cancer cell lines
In all, 10 gastric cancer cell lines with variable histologies were
used in our study and were cultured under appropriate conditions
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sin our laboratory: MKN1, an adenosquamous cell carcinoma;
MKN7, a well-differentiated adenocarcinoma; MKN28 and MKN74,
moderately differentiated adenocarcinomas; MKN45 and KWS-I,
poorly differentiated adenocarcinomas; KATO-III, a signet-ring
cell carcinoma; TSG11, a hepatoid carcinoma; and ECC10 and
ECC12, endocrine cell carcinomas.
Primary gastric cancers
In all, 71 pairs of gastric cancers (40 differentiated and 31
undifferentiated carcinomas; 15 early stage and 56 advanced stage)
and corresponding non-neoplastic gastric mucosa were surgically
obtained from 71 patients. Tissue samples were immediately
frozen and stored at  801C until analysis. All patients received a
median of 36.7 months of follow-up care (range, 1–77 months).
Autopsy samples
Non-neoplastic gastric mucosa samples from noncancer-bearing
stomachs were obtained from 34 autopsies. The autopsies
consisted of 21 males and 13 females, ranging in age from 0.7 to
87 years (mean, 56 years). For most autopsies, tissue samples were
obtained from the upper, middle and lower portions of the
stomach. A total of 91 specimens were obtained, frozen and stored
at  801C until analysis.
DNA and RNA extraction
DNA was extracted from the 10 gastric carcinoma cell lines, 71
primary gastric cancers and their corresponding non-neoplastic
gastric mucosa, and 91 non-neoplastic gastric mucosa from
autopsies using SepaGene (Sanko-Junyaku, Tokyo, Japan). Total
RNA was isolated from the 10 gastric carcinoma cell lines using
TRIZOL reagent (Gibco BRL, Life Technologies, Gaithersburg, MD,
USA).
Bisulfite modification and methylation-specific
polymerase chain reaction (MSP)
Sodium bisulphite treatment of DNA converts all unmethylated
cytosines to uracils, but leaves methylated cytosines unaffected.
Briefly, 2mg aliquots of genomic DNA were denatured with sodium
hydroxide and modified by sodium bisulphite. Samples were then
purified using Wizard DNA purification resin (Promega, Madison,
WI, USA), treated with NaOH, recovered in ethanol and
resuspended in 30ml distilled water. Amplification was carried
out in a 20ml reaction volume containing 2ml GeneAmp PCR Gold
Buffer (PE Applied Biosystems, Foster City, CA, USA), 1.0mM
MgCl2,1 ml each primer, 0.2mM dNTPs and 1U Taq polymerase
(AmpliTaq Gold DNA Polymerase, PE Applied Biosystems). After
heating at 941C for 10min, PCR was performed in a thermal cycler
(GeneAmp 2400, PE Applied Biosystems) for 35 cycles of
denaturation at 941C for 30s, annealing at 541C for 60s and
extension at 721C for 60s, followed by a final 7-min extension at
721C. A positive control (Sss-I methylase-treated DNA) and
negative control (distilled water without DNA) were included in
each amplification. The PCR products were separated on 6%
nondenaturing polyacrylamide gels. The following primer sets
were used: Chfr M forward (50-GTA ATG TTT TTT GAT AGC
GGC-30) and Chfr M reverse (50-AAT CCC CCT TCG CCG-30) for
methylated Chfr sequences; Chfr U forward (50-GGT TGT AAT
GTT TTT TGA TAG TGG T-30) and Chfr U reverse (50-CAA ATC
CCC CTT CAC CA-30) for unmethylated Chfr sequences (Corn et al,
2003).
Reverse transcription–PCR (RT–PCR)
Isolated RNA was reverse transcribed and amplified using the One-
Step RT–PCR System (Gibco BRL). Primer sequences used were:
Chfr forward (50-TGG AAC AGT GAT TAA CAA GC-30) and Chfr
reverse (50-AGG TAT CTT TGG TCC CAT GG-30) for Chfr; and b-
actin forward (50-AAA TCT GGC ACC ACA CCT T-30) and b-actin
reverse (50-AGC ACT GTG TTG GCG TAC AG-30) for b-actin. RT–
PCR products were separated on 3% agarose gels.
5-aza-20-deoxycytidine (5-aza-dC) treatment
To examine the restoration of Chfr expression, two cell lines
(MKN1 and KATO-III) were incubated for 96h with 0.2 or 1mM 5-
aza-dC (Sigma), and then harvested for RNA extraction and RT–
PCR.
Preparation of MSP-positive control
Sss-I methylase (New England BioLabs, Inc., Beverly, MA, USA)
was used to methylate 100mg peripheral blood DNA, which was
modified by sodium bisulphite as described above.
Statistical analysis
Statistical comparisons were performed using Fisher’s exact test,
with Po0.05 considered statistically significant. Survival analysis
was performed using a Kaplan–Meier curve with a log-rank test.
RESULTS
Hypermethylation and expression of Chfr in gastric cancer
cell lines
Chfr promoter hypermethylation was observed in two (MKN1 and
KATO-III) of the 10 cell lines tested (Figure 1). The remaining cells
lines (MKN7, MKN28, MKN45, MKN74, KWS-I, TSG11, ECC10
and ECC12) contained unmethylated Chfr alleles and expressed
abundant Chfr mRNA. MKN1 and KATO-III exhibited loss of Chfr
expression (Figure 1), which was restored after treatment with 5-
aza-dC (Figure 1). Thus, promoter methylation status of Chfr
directly correlated with expression.
Hypermethylation of Chfr in primary gastric cancers,
corresponding non-neoplastic gastric mucosa and autopsy
samples
Hypermethylation of Chfr was detected in 35% (25 of 71) of
primary gastric cancers but only in 5% (four of 71) of the
corresponding non-neoplastic gastric mucosa (Figure 2). Chfr
hypermethylation was observed in only one (1%) of the 91 autopsy
samples. This single sample showing Chfr hypermethylation was
obtained from the lower portion of the stomach from an 82-year-
old-male patient with Parkinson’s disease.
Correlation between Chfr promoter hypermethylation and
clinicopathological parameters
Chfr hypermethylation occurred at a similar frequency in early and
advanced gastric cancers, and no significant correlations between
Chfr promoter methylation status and clinicopathological factors
were observed (Table 1). Methylation status did not significantly
influence event-free survival rate, as analysed by Kaplan–Meier
curve with log-rank test and the Breslow–Gehan–Wilcoxon test
(data not shown).
DISCUSSION
Although CIN is one of the most frequently recognised phenom-
enon in gastric cancer (Abad et al, 1998; Esteban et al, 1999; Russo
et al, 2000), the mitotic checkpoint genes hsMAD2 and hBUB1 are
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(Imai et al, 1999; Tanaka et al, 2001). Checkpoints upstream of the
spindle checkpoint that delays chromosome condensation in
response to mitotic stress are regulated by CHFR. Normal primary
cells and cancer cell lines that express CHFR exhibit delayed entry
into metaphase after treatment with microtubule inhibitors
(Scolnick and Halazonetis, 2000). In contrast, cancer cell lines
that lack CHFR enter metaphase without delay, with ectopic
expression of CHFR necessary and sufficient to restore cell-cycle
delay (Scolnick and Halazonetis, 2000). Recent studies of human
tumours have shown that Chfr inactivation can be due to
hypermethylation of CpGs in the promoter region (Mizuno et al,
2002; Shibata et al, 2002). However, whether Chfr promoter
hypermethylation is involved in gastric cancer has not yet been
determined.
In the present study, we showed that Chfr promoter hyper-
methylation was present in two of 10 (20%) gastric cancer cell lines
and in 25 of 71 (35%) primary gastric cancers. As for non-
neoplastic gastric epithelia, 5% (four of 71) of samples from
cancer-bearing and 1% (one of 91) from noncancer-bearing
stomachs exhibited Chfr promoter hypermethylation. We have
shown that many tumour suppressor and tumour-related genes,
such as APC, DAP-kinase, DCC, E-cadherin, hMLH1, p16, RASSF1A
and RUNX3, exhibit promoter hypermethylation in both
neoplastic and non-neoplastic gastric epithelia at variable
frequencies (Tamura, 2004). While GSTP1 and PTEN promoters
remained unmethylated in both neoplastic and non-neoplastic
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Figure 1 Methylation-specific polymerase chain reaction (A and B),
RT–PCR (C and D) and comparison of Chfr mRNA expression before ( )
and after (þ) 5 aza-dC treatment (E) in gastric cancer cell lines. (A) Chfr-
methylated-sequence-specific PCR and (B) Chfr-unmethylated-sequence-
specific PCR. Methylated Chfr product is present in lanes 1 and 6 (A), while
demethylated Chfr product is present in all lanes except lanes 1 and 6 (B).
(C) Chfr RT–PCR and (D) b-actin RT–PCR (internal control). Chfr
product is absent in lanes 1 and 6 (C). b-actin mRNA is present in all lanes
(D). Lanes: 1, MKN1; 2, MKN7; 3, MKN28; 4, MKN45; 5, MKN74; 6,
KATO-III; 7, KWS-I; 8, TSG11; 9, ECC10; 10, ECC12; P, positive control;
DW, distilled water; and SM, size marker. (E) Treatment with 5 aza-dC
restores Chfr mRNA expression in KATO-III, but does not affect Chfr
expression levels in MKN45.
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Figure 2 Methylation-specific polymerase chain reaction of primary
gastric cancers (T) and their corresponding non-neoplastic gastric mucosa
(N). M, Chfr-methylated-sequence-specific PCR; U, Chf- unmethylated-
sequence-specific PCR; P, positive control; DW, distilled water; and SM,
size marker. Methylated Chfr is present in primary gastric cancers (M123,
M137, M145, M157, M245), whereas non-neoplastic gastric mucosa
samples do not exhibit methylated Chfr.
Table 1 Correlation between Chfr promoter methylation status and
clinicopathological characteristics in gastric cancer patients
Promoter methylation status
Methylated Unmethylated
Number of patients 25 46
Age (years )(mean) 72 66
Gender
Male 20 31 NS
Female 5 15
Stage
Early 6 9 NS
Advanced 19 37
Histological differentiation
Differentiated 13 27 NS
Undifferentiated 12 19
Location
Lower 12 17 NS
Middle 10 15
Upper 2 12
Unknown 1 2
Lymph node metastasis
Present 20 38 NS
Absent 5 8
NS¼not significant by Fisher’s exact probability test. Chfr¼checkpoint with forkhead
associated and ring finger.
i
i
i
#
i
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promoter hypermethylation is highly cancer specific, but is
observed at only a low frequency in gastric cancer (Honda et al,
2002).
Methylation generally increases with age in tissue-specific
manner for different genes (Waki et al, 2003b). In the present
study, the only sample of non-neoplastic gastric mucosa that
exhibited Chfr hypermethylation was obtained from the non-
cancer-bearing stomach of an 82-year-old male patient. In
contrast, Chfr hypermethylation was present in cancer-bearing
stomachs from patients from 66 years of age. Based on these
observations, it appears that age-related Chfr hypermethylation
may constitute a general defect where individuals may become
predisposed to the development of gastric cancer. The cancer
specificity of hypermethylation of a particular promoter can
depend on the CpG site examined (Satoh et al, 2002). Our present
study revealed that Chfr promoter hypermethylation appears to be
one of the most cancer-specific alterations among the various
examples of tumour suppressor and tumour-related gene hyper-
methylation reported to date (Tamura, 2004).
While Chfr promoter hypermethylation is a relatively infrequent
non-neoplastic gastric epithelia, it occurs at similar frequencies in
early and advanced gastric cancers. This suggests that Chfr
promoter hypermethylation may be an early event in gastric
carcinogenesis. DNA aneuploidy has been observed in 50–71% of
gastric cancers and correlates with poor prognosis (Abad et al,
1998; Esteban et al, 1999; Russo et al, 2000). In the present study,
we failed to find a statistically significant correlation between Chfr
hypermethylation and gastric cancer patient survival. Nonetheless,
our results did display a tendency towards a worse prognosis in
patients with tumours that displayed Chfr hypermethylation.
Owing to the lack of a significant correlation between Chfr
methylation status and prognosis, and the relatively low frequency
of Chfr hypermethylation compared to that of DNA aneuploidy,
other gene(s) and/or mechanism(s) are likely to also contribute to
CIN in gastric cancer.
In conclusion, Chfr promoter hypermethylation frequently
occurs as an early event of gastric carcinogenesis. Owing to its
cancer specificity, detection of Chfr promoter methylation could be
useful as a molecular diagnostic marker for gastric cancer.
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